Focus:
News
-
17 January 2020
WuXi Biologics to acquire drug manufacturing plant in Germany
WuXi Biologics has signed an acquisition agreement to take over a Bayer’s drug product manufacturing plant in Leverkusen, Germany.
-
17 January 2020
Novo Nordisk secures FDA expanded indication for Ozempic
The US Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Ozempic (semaglutide).
-
17 January 2020
Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule
Merck (MSD) has completed its previously announced acquisition of US-based biopharmaceutical company ArQule.
-
16 January 2020
Dermavant sells Tapinarof commercial rights in Japan
Dermavant Sciences, a subsidiary of Roivant Sciences, has signed an exclusive agreement to sell the development and commercial rights of tapinarof in Japan.
-
16 January 2020
FDA grants Clovis’ Rubraca fast track designation for prostate cancer
Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration (FDA) for Rubraca (rucaparib) as a monotherapy for BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer (mCRPC)...
-
16 January 2020
BMS secures FDA priority review for NSCLC treatment combination
Bristol-Myers Squibb Company (BMS) has secured the US Food and Drug Administration (FDA) priority review for a drug combination to treat metastatic or recurrent non-small cell lung cancer (NSCLC).
-
16 January 2020
Galapagos expands fibrosis research collaboration with Fibrocor
Galapagos has expanded its research collaboration with Candian firm Fibrocor Therapeutics, which develops tissue-specific therapeutics for fibrotic diseases.
-
15 January 2020
Japan approves ViiV’s two drug regimen Dovato for HIV
ViiV Healthcare’s human immunodeficiency virus (HIV) drug Dovato (dolutegravir 50mg/lamivudine 300mg) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW).
-
14 January 2020
Takeda partners Charles River to develop preclinical candidates
Takeda Pharmaceutical Company has teamed up with Charles River to deliver preclinical candidates across its four core therapeutic areas.
-
14 January 2020
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US company Incyte to continue the global development and commercialisation of the former’s tafasitamab (MOR208) for...
Close
Close
Close
Go Top
